Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Slow vs Rapid Titration of Subcutaneous Remodulin in PAH
NCT02893995Phase 4Withdrawn
- Sponsor
- United Therapeutics Corporation
- Start
- Feb 2017
- Primary completion
- Apr 2018
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of treprostinil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by United Therapeutics Corporation. Primary endpoints: Incidence of Adverse Events at 16 weeks, Change in Patient Reported Site Pain at 16 weeks and 1 more. Planned start Feb 2017; status: withdrawn.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02893995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02893995.